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Abstract
Introduction and hypothesis Urinary incontinence is preva-
lent in postmenopausal women and spayed dogs and is asso-
ciated with decreased estrogen plasma concentrations. The
objective of the study was to investigate the expression of
estrogen receptors (ER) in the urethra of sexually intact,
ovariectomized, and estrogen-substituted ovariectomized
ewes.
Methods Paraffin cross-sections from each urethral quarter
were immunohistochemically analyzed. The reactivity of ER
was semiquantitatively assessed employing an immunoreac-
tive score (IRS).
Results In contrast to ERβ, ERα was identified in all urethral
compartments; the highest IRS was detected in the epithelium
of the distal urethra. The immunoreactivity and distribution of
ERα did not differ among groups. Highly significant differ-
ences in ERα concentrations were observed between consec-
utive urethral quarters in each group.
Conclusions Neither ovariectomy nor ovariectomy and estro-
gen substitution seem to have a significant effect on overall
urethral ERα concentration. The results demonstrate that the
precise location of the investigated urethral part is crucial to
the reliable evaluation or possible comparison of ERα
concentrations.
Keywords Estrogen receptor . Immunohistochemistry .
Ovariectomy . Sheep . Urethra . Urinary incontinence
Abbreviations
ANOVA Factorial analysis of variance
CEE Conjugated equine estrogen
ER Estrogen receptor
ERT Estrogen replacement therapy
IRS Immunoreactive score
NOC Non-operated control
OVE Estrogen-substituted ovariectomized
OVX Ovariectomized
UI Urinary incontinence
U1/4 Urethral quarter 1 (connecting with urinary
bladder)
U4/4 Urethral quarter 4 (connecting with vaginal
vestibule)
WHI Women’s Health Initiative
Introduction
Urinary incontinence is a common lower urinary tract disorder
in both women and female dogs. In women, it is prevalent in
the postmenopausal period, whereas in dogs it is the most
common undesirable effect of spaying [1–3]. The pathophys-
iological mechanism of this lower urinary tract dysfunction is
not completely understood. Menopause in women and spay-
ing in dogs are accompanied by decreased ovarian steroid
hormone plasma concentrations and associated with reduced
urethral closure pressures and impaired closure function of the
urethra [4–7]. Estrogen deficiency is believed to play an
important role in the development of urinary incontinence in
both species, as estrogen is essential for physiological main-
tenance and the integrity of the female urogenital tract. The
specific effects of estrogens are classically mediated via their
interaction with corresponding nuclear receptors [8, 9]. Apart
from other organs and tissues, estrogen receptors have been
H. R. Augsburger :C. Führer
Institute of Veterinary Anatomy, Vetsuisse Faculty, University of
Zurich, Zurich, Switzerland
H. R. Augsburger (*)
Institute of Veterinary Anatomy, University of Zürich,
Winterthurerstrasse 260, 8057 Zürich, Switzerland
e-mail: augsbhr@vetanat.uzh.ch
Int Urogynecol J (2014) 25:657–662
DOI 10.1007/s00192-013-2275-8
shown to be present in the female urethra of humans [9–11],
dogs [12], and laboratory animals [13–15]. The urethra is
responsible for urinary continence depending on several ure-
thral tissue components, such as smooth and striated muscu-
lature, the vascular plexus, connective tissue, as well as
periurethral structures [16, 17].
A suitable experimental animal model for urinary inconti-
nence research has been lacking to date [18]. An appropriate
animal model for the investigation of urinary incontinence
could reduce the pitfalls associated with studying the disease
in humans. The sheep seems to be a promising animal for this
purpose. Ovariectomized sheep, for example, have been wide-
ly used as a model for postmenopausal osteoporosis research
[19]. Ewes are seasonal polyestrous and their estrous cycle
extends over a period of about 17 days. The rather unspectac-
ular estrus lasts around 24 h and gestation averages 147 days.
This study was undertaken to identify estrogen receptors
(ER) in the ovine urethra and to provide insights into the
effects of ovariectomy and estrogen substitution on their ex-
pression in the different urethral tissue compartments, using
immunohistochemistry and semiquantitative analysis.
Moreover, the potential of the sheep as an animal model for
certain aspects of urinary incontinence was evaluated.
Materials and methods
Animals
Eighteen aged Merino ewes (5 years old) were obtained from
a single source and selected for uniformity of size, conforma-
tion, body condition, and absence of pregnancy. Their average
body weight was 58.7 kg. Twelve randomly selected animals
were ovariectomized under general anesthesia via a small
midline laparotomy incision, while the remaining 6 served
as non-operated controls. Furthermore, half of the operated
sheep received estradiol implants as described by Adams et al.
[20]. The implants were placed subcutaneously in the hairless
region of the chest wall below the axilla through a small
incision. They released a total of 22.5 μg estradiol-17β
(Sigma, St. Louis, MO, USA) per 24 h. The treatment groups
(n =6) were therefore: non-operated control (NOC), ovariec-
tomized (OVX), and estrogen-substituted ovariectomized
(OVE). All animals were maintained under identical environ-
mental conditions for 6 months, at which time they were
slaughtered.
Venous blood samples were collected at 1, 3, and 6 months
post-operatively. Plasma estradiol-17ß concentrations were
measured using the method described by Webb et al. [21],
involving an affinity chromatography extraction procedure
followed by double-antibody radioimmunoassay. All animal
procedures were approved by theMurdoch University Animal
Ethics Committee (R1031/04).
Tissue processing
After slaughter of the sheep, the bladder and urethra including the
caudal part of the vagina and the vaginal vestibule were removed
from the pelvic cavity. Subsequently, each urethra was excised at
the level of the internal and external urethral orifices and
mounted on a wooden spatula. The urethrae were then
immersion-fixed with Histochoice® tissue fixative (Amresco
Inc., Solon, OH, USA) for 48 h and split into four parts of equal
length (urethral quarters 1–4), whereby quarter 1 (U1/4) was
adjacent to the bladder (proximal) and U4/4 connected with the
vaginal vestibule (distal). The fixed specimens were routinely
embedded in paraffin and cut into serial cross-sections of 5μm in
thickness. For immunohistochemical analysis, three sections
from the middle of each urethral quarter were mounted on
adhesive SuperFrost Plus® glass-slides (Menzel-Gläser,
Braunschweig, Germany) and heat dried at 60 °C for 30 min.
Immunohistochemistry
Immunostaining of ER was performed using the streptavidin–
biotin complex peroxidase technique (Dako, Glostrup,
Denmark). The sections were deparaffinized and rehydrated
in graded ethanol. For retrieval of receptor epitopes, sections
were subjected to citrate-based microwave processing (3×
5 min, 103 °C, 600 W) in target retrieval solution pH 9
(Dako). Endogenous peroxidase activity was blocked with
3 % hydrogen peroxide in distilled water for 10 min.
Following washing in Tris-buffered saline (TBS, 5 min), the
sections were treated with an avidin/biotin blocking kit
(Vector Laboratories, Burlingame, CA, USA) to inhibit non-
specific staining due to endogenous avidin and biotin. After a
further wash in TBS, they were covered with 1 % normal goat
serum (Kirkegaard & Perry, Gaithersburg, MD, USA) for
20 min and serum-free protein block (Dako) for 10 min to
eliminate nonspecific protein binding. Following removal of
excess serum, the primary antibodies, monoclonal mouse anti-
human ERα (1ID5, Dako; 1:50) and monoclonal mouse anti-
human ERβ1 (PPG5/10, Dako; 1:50), were applied and
allowed to incubate for 20 h at 4 °C in a humidity chamber.
The sections were then rinsed with TBS and incubated with a
biotinylated rabbit anti-mouse secondary antibody (Dako) for
30 min at room temperature before being washed twice in
TBS, followed by treatment with a peroxidase conjugated
streptavidin label (Dako) for 30 min and a further wash in
TBS. The streptavidin–biotin peroxidase reaction was devel-
oped with diaminobenzidine (DAB, Dako) as chromogen.
The sections were then rinsed with distilled water, counter-
stained with Mayer’s haemalaun, dehydrated and mounted in
Pertex® (Medite, Nunningen, Switzerland).
Negative controls were obtained by replacing the primary
antibody with non-immune mouse-IgG (Dako). Positive con-
trols were performed employing uterine tissue.
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The immunohistochemical expression and distribution of
investigated ER were evaluated by the authors individually at
a magnification of ×400 by use of an image analysis system
(AnalySIS, Soft Imaging System, Münster, Germany), com-
prising a light microscope fitted with a digital camera
(Colorview 12, Soft Imaging System). The staining intensity
of 500 nuclei was assessed in randomly selected microscopic
fields of the urethral compartments epithelium, propria, and
smooth musculature using an immunoreactive score (IRS)
described by Schäubli et al. [22]. Immunoreactivity was
scored as negative (0), weak (1), intermediate (2), or strong
(3), correlating with the absence of brown, light brown, and
dark brown staining respectively. Results were expressed as a
percentage of positively stained nuclei of the total counted per
urethral compartment.
Statistical analysis
Mean ± standard deviation values were computed for all
immunoreactivity and hormone data. Data were assessed for
normal distribution and subjected to a one-way factorial anal-
ysis of variance (ANOVA) by use of StatView® software (5.1;
SAS Institute, Cary, NC, USA) to evaluate differences in
estradiol and estrogen receptor concentrations among groups
Fig. 1 Representative
immunohistochemical reactivity
of estrogen receptors-α (brown
staining) in the nuclei (arrows) of
the epithelium, propria, and
smooth musculature in urethral
quarters 2–4 (U2/4–U4/4) of the
three groups NOC, OVE, and
OVX. Bars, 100 μm. Smooth
musculature in a U2/4 and b U3/
4 of NOC: no staining of striated
musculature (asterisks).
Epithelium in c U4/4 of OVE and
d OVX: overall, no difference
between groups. Epithelium in e
U2/4 and f U3/4 of OVE:
significant difference between
consecutive urethral quarters.
Propria in g U2/4 and h U3/4 of
OVX: significant difference
between consecutive urethral
quarters
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as well as differences in immunoreactivity between urethral
quarters within groups. Significant differences were assessed
using the Bonferroni–Dunn procedure as post hoc test. In
order to demonstrate a possible relationship between estradiol
concentrations at the time of slaughter and the immunohisto-
chemical expression of urethral estrogen receptors, the corre-
lation coefficients between variables and the corresponding
regression analysis with 95 % confidence intervals were
calculated.
Results
Distinct immunohistochemical expression of ERα was con-
sistently detected in the epithelium, propria, and smooth mus-
culature compartments throughout the urethra of all ewes. In
contrast, ERβ could not be identified. Immunolocalization of
ERα was confined to the nuclei revealing differential staining
intensities (Fig. 1). The striated muscle fibers showed no
evidence of positive immunolabelling (Fig. 1b).
Overall, there were no significant differences in the IRS of
the whole urethra among groups (Fig. 1c, d). However, dis-
tinct differences of statistical relevance were observed in the
scores between adjacent urethral quarters within all groups.
Apart from the smooth musculature, significant increases (p <
0.01/0.001) in ERα concentrations in the epithelium and
proprial connective tissue were ascertained between consecu-
tive urethral quarters from the cranial to the caudal end of the
urethra in each group (Figs. 1e–h, 2, 3 and Table 1).
Furthermore, differences in the IRS of the three urethral
compartments analyzed were evident among groups. The
IRS of the epithelium was significantly increased (p <0.002)
in the OVX relative to the NOC and OVE sheep. The opposite
was true for the smooth musculature: the ERα concentration
in the smooth musculature proved to be significantly lower (p
<0.001) in the OVX than in the NOC and OVE animals.
Although not always statistically meaningful, mean plasma
estradiol concentrations were lower in the OVX group than in
groups NOC and OVE (Table 2). No correlation was found
between estradiol plasma concentrations at the time of slaugh-
ter and the corresponding IRS.
Discussion
In contrast to numerous immunohistochemical studies that
only rely on small biopsies, this investigation was conducted
on full urethral cross-sections throughout the entire organ
giving a comprehensive insight into the immunostaining
and distribution pattern of ER in the different urethral tissue
compartments of OVX, OVE, and NOC ewes. The results
of the present study revealed the immunohistochemical
expression of ERα in the nuclei of the urethral epithelium,
the proprial connective tissue, and the smooth musculature.
These findings show the female ovine urethra to be a target
organ for the action of estrogen. Overall, no significant
differences in the IRS pertaining to the whole urethra were
observed among groups. This finding concurs with studies
carried out by Blakeman et al. [10], who assessed the
incidence and distribution of ER throughout the human
female lower urinary tract and compared receptor expres-
sion in women of various estrogen statuses. They consis-
tently detected ER in the squamous epithelium of the lower
urinary tract of all women and found no significant
variation in histological score irrespective of estrogen
status. This observation was interpreted as the female
urinary tract being potentially receptive to the actions of
estrogen at all times.
Fig. 3 Mean ERα IRS values (± SD) of the propria compartment in
urethral quarters 1–4 of the three groups NOC, OVE, and OVX. Asterisk
significant differences between consecutive urethral quarters (p <0.01) in
groups NOC and OVE. Asterisk1, 2 Significant differences between
urethral quarters (p <0.01) in group OVX
Fig. 2 Mean ERα IRS-values (± SD) of the epithelium compartment in
urethral quarters 1–4 of the three groups non-operated controls (NOC),
estrogen-substituted ovariectomized (OVE ), and ovariectomized
(OVX). Asterisk significant differences between consecutive urethral
quarters (p <0.01)
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However, in our study significant differences in the immu-
nohistochemical expression of ERα in the epithelial and
smooth muscle compartments could be established among
groups. The observation of the significantly decreased urethral
smooth muscle IRS in OVX compared with NOC and OVE
groups is particularly noteworthy since the smooth muscula-
ture consisting of essentially circularly oriented fibers is
regarded as the most important contributory factor to urinary
continence [16, 23]. Estrogen has been shown to increase the
sensitivity of the urethral smooth musculature to α-adrenergic
stimulation [23]. Decreased plasma estrogen levels as a sequel
to ovariectomy and the consequent diminished adrenergic
sensitivity of the smooth musculature may result in atrophy
and/or loss of muscle fibers and this, in turn, could affect the
urethral closure mechanism and increase the risk of urinary
incontinence development. The role of estrogen replacement
therapy (ERT) in postmenopausal and postspaying urinary
incontinence (UI) has long been controversial [24–27].
However, according to a more recent publication by investi-
gators of the Womens Health Initiative (WHI) [28] ERT has
no beneficial effects with regard to UI. The results from this
large, double-blind, placebo-controlled, randomized clinical
trial, conducted in multiple centers with healthy postmeno-
pausal women, indicate that postmenopausal hormone therapy
does not prevent any type of UI. On the contrary, both conju-
gated equine estrogen (CEE) alone and CEE plus
medroxyprogesterone acetate increased the risk of new onset
UI among continent women and worsened the characteristics
of UI among symptomatic women. DuBeau [29], who evalu-
ated this WHI study concludes that both the scientific rigor of
theWHI trial and the issues it raises should prompt continuing
investigation of the basic science of estrogen in normal and
aging lower urogenital tract and pelvic floor function, and lead
to further treatment trials (particularly with topical estrogens)
that address the methodological issues of unblinding, UI char-
acterization, patient targeting, and comprehensive outcomes
assessment.
The reduced concentration of ERα in the smooth muscu-
lature of the OVX could be the consequence of lower plasma
estrogen levels in this group relative to the other two. The
decreased smooth muscle IRS, however, could also be attrib-
uted to a reduction in the urethral smooth muscle mass of
OVX. In a previous study dealing with the stereological
analysis of urethral tissue components in sexually intact and
spayed female dogs, we demonstrated decreased smooth mus-
cle volumes in the urethra of ovariohysterectomized dogs
compared with the intact animals [16].
We failed in our efforts to detect ERβ in all urethral tissue
compartments of the groups investigated. In contrast, Tincello
et al. [9], who studied ER isoforms in the lower urinary tract of
pre- and postmenopausal women, detected ERβ immuno-
staining in the urethra and the transitional epithelium of the
bladder. Furthermore, they found that hormonal status had no
effect on the ERβ staining pattern. The deficiency of ERβ
immunoreactivity in our study does not necessarily imply the
Table 2 Plasma estradiol concentrations (mean ± standard deviation) of
non-operated control (NOC ), estrogen-substituted ovariectomized
(OVE), and ovariectomized (OVX) sheep (n =6) at 1, 3, and 6 months
post-operatively (mpo)
Group Plasma estradiol concentrations (pg/ml)
1 mpo 3 mpo 6 mpo
NOC 1.04±0.69a 1.36±0.79 1.36±0.98
OVE 2.01±0.94a, b 2.42±1.37c 1.14±0.38
OVX 0.59±0.11b 0.68±0.26c 0.64±0.28
a, b Significant differences between group OVE and groups NOC/OVX
(p <0.001)
c Significant difference between groups OVE and OVX (p<0.05)
Table 1 Immunoreactive scores
(mean ± standard deviation) of
estrogen receptor α in the urethral
compartments epithelium,
propria, and smooth musculature
of urethral quarters 1–4 (U1/4–
U4/4) of NOC, OVE, OVX sheep
(n =6)
a Significant differences between
consecutive urethral quarters in
corresponding compartments
within groups (p <0.01)
Group Urethral quarter Urethral compartment
Epithelium Propria Smooth musculature
NOC U1/4 53.3±83.9a 143.7±39.4a 317.6±44.3a
U2/4 192.5±106.4a 174.7±41.8a 222.7±19.2a
U3/4 329.0±59.6a 236.7±30.7a 183.1±28.3a
U4/4 424.6±95.5a 307.7±30.9a 192.7±22.3
OVE U1/4 90.1±43.7a 157.1±31.1a 190.0±23.3a
U2/4 233.9±85.7a 196.6±21.4a 221.5±34.8a
U3/4 308.6±66.8a 248.4±35.7a 254.4±34.4a
U4/4 299.4±52.3 297.0±30.0a 306.3±40.4a
OVX U1/4 33.1±27.1a 136.9±27.4a 303.5±22.4a
U2/2 123.3±74.0a 189.0±50.9a 284.4±24.8a
U3/4 239.9±54.2a 269.1±34.3a 266.3±27.6a
U4/4 280.1±46.3a 296.0±36.6a 245.3±39.4
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absence of ERβ. The negative staining might either be due to
the lack of affinity and/or specificity of the antibody used or
may be attributable to loss of antigenicity upon tissue fixation
and/or processing. Among other confounding factors, these
are the main general limitations of staining fixed antigens by
immunohistochemistry.
The sheep has considerable potential as an animal model
for certain aspects of human urinary incontinence research
because of similar urethral and bladder morphology as well
as similar hormone cycles and profiles. In addition, the sheep
is docile, easy to handle, relatively inexpensive, and better
accepted in society as an experimental animal than companion
animals such as dogs and cats [30].
In conclusion, this study revealed that the nuclear ERα
concentration in ovine urethral tissues does not seem to cor-
relate with estrogen status. Furthermore, the findings ascertain
that the precise location of the urethral part investigated is
crucial to the reliable evaluation or possible comparison of
ERα concentrations. This considerable potential of the sheep
as an animal model for human urinary incontinence research
warrants further evaluation.
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